Huntington Disease

Fine-motor endpoints for Huntington disease programs

Huntington disease trials rely on the Unified Huntington Disease Rating Scale (UHDRS) total motor score. NeuroQuantix adds continuous kinematic measurement of chorea-related disruption, fine-motor slowing, and coordination loss during a brief spiral drawing, for antisense oligonucleotide, gene-silencing, and symptomatic programs that need sensitivity to early motor change.

Published evidence on digitized spiral analysis supports continuous, rater-independent motor measurement; the strength of that evidence for this condition is stated on this page. NeuroQuantix standardizes this evidence into a pre-specified endpoint for your program. Learn more about huntington disease from the NINDS/NIH overview.

Discuss Your Program View Technical Data

Continuous

Chorea Disruption

Trajectory deviation and velocity irregularity

Velocity

Fine-Motor Slowing

Peak and mean drawing velocity across the assessment

None

Rater Dependence

Computed metrics

Limited

Evidence Status

Scoping review, Wang et al., 2025

Limitations of UHDRS-TMS

The The Unified Huntington Disease Rating Scale, Total Motor Score (UHDRS-TMS) is the current gold standard for huntington disease assessment in clinical trials. These are its documented limitations.

The UHDRS total motor score is the accepted regulatory motor measure in Huntington disease and remains the anchor

It sums ordinal ratings across chorea, dystonia, oculomotor, bradykinesia, rigidity, and gait items, so an effect on fine-motor control is diluted in the composite

Observer ratings of chorea are variable between raters and sensitive to the examination moment

Early and premanifest motor change can sit below the resolution of ordinal items for years

Published spiral evidence in Huntington disease is limited; the platform is positioned for exploratory use and natural history work

The Huntington Disease Measurement Challenge

Huntingtin-lowering and symptomatic programs need to show motor benefit early, in a disease whose composite motor score changes slowly and whose chorea ratings vary with the rater and the moment. A continuous, rater-independent measure of fine-motor control gives these programs a domain-specific signal beside the UHDRS. NeuroQuantix provides it as a pre-specified exploratory endpoint, with the current evidence status stated plainly.

Clinical Applications

Antisense oligonucleotide and gene-silencing trials as an exploratory fine-motor endpoint

Natural history studies in premanifest and early manifest populations

Symptomatic chorea programs beside the UHDRS total motor score

Published Evidence

Evidence from peer-reviewed publications supporting digital kinematic endpoints for huntington disease assessment. View the full evidence base.

Continuous Fine-Motor Measurement

Spiral kinematics measure velocity, smoothness, and trajectory error as continuous variables, providing resolution below the step size of ordinal motor items.

Scoping review: Wang S, et al. Movement Disorders Clinical Practice, 2025

Statistical Power Advantage

Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on the NeuroQuantix platform page.

View Power Visualization

Frequently Asked Questions

What are the limitations of the UHDRS motor score for Huntington disease trials?

The UHDRS total motor score is a composite of ordinal observer ratings across many motor domains. It carries inter-rater variability, dilutes domain-specific effects, and resolves early motor change poorly. It remains the accepted anchor; a continuous fine-motor measure beside it adds sensitivity for programs targeting early disease.

How does NeuroQuantix measure motor change in Huntington disease?

A brief spiral drawing yields continuous measures of chorea-related trajectory disruption, drawing velocity, smoothness, and coordination. Each is preserved separately rather than summed, so a fine-motor treatment effect is measured directly. The metrics are computed, not rated, and can be pre-specified as an exploratory endpoint beside the UHDRS.

Is spiral analysis validated in Huntington disease?

Evidence is limited relative to Parkinson disease and essential tremor. The appropriate use today is as an exploratory endpoint or in natural history studies that establish upper-limb progression rates, generating the within-program evidence needed to promote the measure later.